154 related articles for article (PubMed ID: 21419590)
1. [Bronchiolar-alveolar carcinoma: From concept to innovative therapeutic strategies].
Wislez M; Lavolé A; Gounant V; Antoine M; Cadranel J
Presse Med; 2011 Apr; 40(4 Pt 1):389-97. PubMed ID: 21419590
[TBL] [Abstract][Full Text] [Related]
2. [Other thoracic cancers. Bronchioloalveolar carcinoma and adenocarcinoma with bronchioloalveolar carcinoma feature: a clinico-pathological spectrum].
Cadranel J; Lavolé A; Gounant V; Wislez M
Rev Mal Respir; 2008 Oct; 25(8 Pt 2):3S196-202. PubMed ID: 18971846
[TBL] [Abstract][Full Text] [Related]
3. [Bronchioloalveolar carcinoma and adenocarcinoma with bronchioloalveolar features: a clinico-pathological spectrum].
Cadranel J; Lavolé A; Gounant V; Wislez M
Rev Mal Respir; 2007 Oct; 24(8 Pt 2):6S165-70. PubMed ID: 18235410
[TBL] [Abstract][Full Text] [Related]
4. [Clinical types of thoracic cancer. Bronchiolo-alveolar carcinoma and adenocarcinoma with bronchioloalveolar features: a clinico-pathological spectrum].
Cadranel J; Lavolé A; Gounant V; Wislez M
Rev Mal Respir; 2006 Nov; 23(5 Pt 3):16S158-16S163. PubMed ID: 17268353
[TBL] [Abstract][Full Text] [Related]
5. Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib.
Wislez M; Antoine M; Baudrin L; Poulot V; Neuville A; Pradere M; Longchampt E; Isaac-Sibille S; Lebitasy MP; Cadranel J
Lung Cancer; 2010 May; 68(2):185-91. PubMed ID: 19581016
[TBL] [Abstract][Full Text] [Related]
6. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.
Miller VA; Riely GJ; Zakowski MF; Li AR; Patel JD; Heelan RT; Kris MG; Sandler AB; Carbone DP; Tsao A; Herbst RS; Heller G; Ladanyi M; Pao W; Johnson DH
J Clin Oncol; 2008 Mar; 26(9):1472-8. PubMed ID: 18349398
[TBL] [Abstract][Full Text] [Related]
7. [Therapeutic management of extensive bronchiolo-alveolar adenocarcinoma: chemotherapy or inhibitors of epidermal growth factor receptor tyrosine kinase?].
Cadranel J; Wislez M; Gounant V; Lavolé A; Antoine M; Milleron B
Rev Pneumol Clin; 2007 Jun; 63(3):147-54. PubMed ID: 17675938
[TBL] [Abstract][Full Text] [Related]
8. IFCT-0401 Trial: a phase II study of gefitinib administered as first-line treatment in advanced adenocarcinoma with bronchioloalveolar carcinoma subtype.
Cadranel J; Quoix E; Baudrin L; Mourlanette P; Moro-Sibilot D; Morere JF; Souquet PJ; Soria JC; Morin F; Milleron B;
J Thorac Oncol; 2009 Sep; 4(9):1126-35. PubMed ID: 19574932
[TBL] [Abstract][Full Text] [Related]
9. The bronchioloalveolar carcinoma and peripheral adenocarcinoma spectrum of diseases.
Garfield DH; Cadranel JL; Wislez M; Franklin WA; Hirsch FR
J Thorac Oncol; 2006 May; 1(4):344-59. PubMed ID: 17409882
[TBL] [Abstract][Full Text] [Related]
10. Bronchioloalveolar carcinoma: the case for two diseases.
Garfield DH; Cadranel J; West HL
Clin Lung Cancer; 2008 Jan; 9(1):24-9. PubMed ID: 18282354
[TBL] [Abstract][Full Text] [Related]
11. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features.
Sun PL; Seol H; Lee HJ; Yoo SB; Kim H; Xu X; Jheon S; Lee CT; Lee JS; Chung JH
J Thorac Oncol; 2012 Feb; 7(2):323-30. PubMed ID: 22237264
[TBL] [Abstract][Full Text] [Related]
12. Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma.
Kris MG; Giaccone G; Davies A; Fukuoka M; Garfield DH; Jassem J; Quoix EA; Sandler AB; Scagliotti GV; Van Meerbeeck JP; West H
J Thorac Oncol; 2006 Nov; 1(9 Suppl):S32-6. PubMed ID: 17409999
[TBL] [Abstract][Full Text] [Related]
13. [EGFR tyrosine kinase inhibitors as a targeted therapy for bronchioloalveolar carcinoma of the lung: a case report of a clinically prompt and intensive response and literature review].
Svoboda M; Fabian P; Slabý O; Stanková M; Lakomý R; Nemecek R; Vyzula R
Klin Onkol; 2010; 23(4):224-30. PubMed ID: 20806820
[TBL] [Abstract][Full Text] [Related]
14. Response to gefitinib in bronchioloalveolar carcinoma in the absence of EGFR mutation.
Taja-Chayeb L; Candelaria M; Brom R; Trejo-Becerril C; Meza F; Duenas-Gonzalez A
Lung Cancer; 2005 Nov; 50(2):259-63. PubMed ID: 16009451
[TBL] [Abstract][Full Text] [Related]
15. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
16. Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma.
Hata A; Katakami N; Fujita S; Kaji R; Imai Y; Takahashi Y; Nishimura T; Tomii K; Ishihara K
J Thorac Oncol; 2010 Aug; 5(8):1197-200. PubMed ID: 20661086
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer.
Pallis AG; Voutsina A; Kentepozidis N; Giassas S; Papakotoulas P; Agelaki S; Tryfonidis K; Kotsakis A; Vamvakas L; Vardakis N; Georgoulias V
Clin Lung Cancer; 2012 Mar; 13(2):129-35. PubMed ID: 22000696
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor mutation and p53 overexpression during the multistage progression of small adenocarcinoma of the lung.
Yoo SB; Chung JH; Lee HJ; Lee CT; Jheon S; Sung SW
J Thorac Oncol; 2010 Jul; 5(7):964-9. PubMed ID: 20512074
[TBL] [Abstract][Full Text] [Related]
19. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.
Hirsch FR; Varella-Garcia M; McCoy J; West H; Xavier AC; Gumerlock P; Bunn PA; Franklin WA; Crowley J; Gandara DR;
J Clin Oncol; 2005 Oct; 23(28):6838-45. PubMed ID: 15998906
[TBL] [Abstract][Full Text] [Related]
20. Unusual chemosensitivity of advanced bronchioalveolar carcinoma after gefitinib response and progression: a case report.
Dziadziuszko R; Siemiatkowska A; Limon J; Rzyman W; Jassem J; Bunn PA; Varella-Garcia M; Hirsch FR
J Thorac Oncol; 2007 Jan; 2(1):91-2. PubMed ID: 17410018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
